We rank companies based on fund manager, research analyst and news sentiment
ADCT stock icon

ADC Therapeutics
ADCT

$4.68
0.85%
 

About: ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Employees: 274

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 8 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

59% more capital invested

Capital invested by funds: $35.4M [Q3] → $56.3M (+$20.9M) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

10.84% less ownership

Funds ownership: 48.93% [Q3] → 38.1% (-10.84%) [Q4]

12% less funds holding

Funds holding: 41 [Q3] → 36 (-5) [Q4]

30% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 10

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $2.82K

Research analyst outlook

8 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$3
36%
downside
Avg. target
$7.88
68%
upside
High target
$11
135%
upside

8 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Robert Burns
92%upside
$9
Buy
Reiterated
15 Apr 2024
Guggenheim
Michael Schmidt
135%upside
$11
Buy
Initiated
28 Mar 2024
RBC Capital
Gregory Renza
71%upside
$8
Outperform
Reiterated
14 Mar 2024
HC Wainwright & Co.
Robert Burns
92%upside
$9
Buy
Reiterated
6 Mar 2024
RBC Capital
Gregory Renza
71%upside
$8
Outperform
Maintained
26 Feb 2024

Financial journalist opinion